- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383–1389 (1994)
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7–22 (2002)
- Parascandola J: From germs to genes: trends in drug therapy, 1852–2002. Pharm. Hist. 44, 3–11 (1852)
- Cannon CP, Braunwald E, McCabe CH et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495–1504 (2004)
- Nissen SE, Tuzcu EM, Schoenhagen P et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071–1080 (2004)
- Blum CB: Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am. J. Cardiol. 73, 3D–11D (1994)
- Ballantyne CM, Corsini A, Davidson MH et al.: Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med. 163, 553–564 (2003)
- Rosenson RS: Current overview of statininduced myopathy. Am. J. Med. 116, 408–416 (2004)
- Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA 289, 1681–1690 (2003).
- Summarizes possible statin myopathic complaints, their frequency during controlled clinical trials, possible mechanisms and management.
- Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C: ACC/AHA/NHLBI clinical advisory on the use and safety of statins 12J. Am. Coll. Cardiol. 40, 567–572 (2002)
- Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis associated with lovastatin–gemfibrozil combination therapy. JAMA 264, 71–75 (1990).
- This classic review is among the first collection of cases emphasizing that gemfibrozil use is frequent in patients with clinically important statin myopathy.
- de Lemos JA, Blazing MA, Wiviott SD et al.: Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA 292, 1307–1316 (2004)
- Clarkson PM, Hubal MJ: Exercise-induced muscle damage in humans. Am. J. Phys. Med. Rehabil. 81, S52–S69 (2002)
- Sayers SP, Clarkson PM, Rouzier PA, Kamen G: Adverse events associated with eccentric exercise protocols: six case studies. Med. Sci. Sports Exerc. 31, 1697–1702 (1999)
- Clarkson PM, Kearns AK, Rouzier P, Rubin R, Thompson PD: Serum creatine kinase levels and renal function measures in exertional muscle damage. Med. Sci. Sports Exerc. (2005)
- Phillips PS, Haas RH, Bannykh S et al.: Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med. 137, 581–585 (2002).
- First report of cases with biopsy documented myopathy despite normal creatinine kinase (CK) levels. This article changed the way most physicians think of statin myopathy and emphasized the absence of CK elevations in many affected patients.
- Omar MA, Wilson JP, Cox TS: Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann. Pharmacother. 35, 1096–1107 (2001)
- Prueksaritanont T, Subramanian R, Fang X et al.: Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Dispos. 30, 505–512 (2002).
- First report emphasizing that statins can be metabolized by glucuronidation. This discovery explained why gemfibrozil, which inhibits glucuronidation but has little effect of cytochrome P450 metabolism, exacerbates statin myopathy.
- Bottorff M, Hansten P: Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians. Arch. Intern. Med. 160, 2273–2280 (2000)
- The statin wars: why AstraZeneca must retreat. Lancet 362, 1341 (2003)
- Gharavi AG, Diamond JA, Smith DA, Phillips RA: Niacin-induced myopathy. Am. J. Cardiol. 74, 841–842 (1994)
- Langer T, Levy R: Acute muscular syndrome associated with administration of clofibrate. N. Engl. J. Med. 279, 856–858 (1968)
- Morita I, Sato I, Ma L, Murota S: Enhancement of membrane fluidity in cholesterol-poor endothelial cells pretreated with simvastatin. Endothelium 5, 107–113 (1997)
- Nakahara K, Yada T, Kuriyama M, Osame M: Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors. Biochem. Biophys. Res. Commun. 202, 1579–1585 (1994)
- Bifulco M, Laezza C, Aloj SM, Garbi C: Mevalonate controls cytoskeleton organization and cell morphology in thyroid epithelial cells. J. Cell. Physiol. 155, 340–348 (1993)
- Sacher J, Weigl L, Werner M, Szegedi C, Hohenegger M: Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J. Pharmacol. Exp. Ther. 314, 1032–1041 (2005)
- Flint OP, Masters BA, Gregg RE, Durham SK: Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol. Appl. Pharmacol. 145, 91–98 (1997)
- Laaksonen R, Riihimaki A, Laitila J, Martensson K, Tikkanen MJ, Himberg JJ: Serum and muscle tissue ubiquinone levels in healthy subjects. J. Lab. Clin. Med. 125, 517–521(1995)
- Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC: Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol. Pathol. 33, 246–257 (2005)
- De Pinieux G, Chariot P, Ammi-Said M et al.: Lipid-lowering drugs and mitochondrial function: effects of HMGCoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br. J. Clin. Pharmacol. 42, 333–337 (1996)
- Rotig A, Appelkvist EL, Geromel V et al.: Quinone-responsive multiple respiratorychain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 356, 391–395 (2000)
- Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK: Simvastatininduced rhabdomyolysis followed by a MELAS syndrome. Am. J. Med. 94, 109–110 (1993)
- Laaksonen R, Jokelainen K, Laakso J et al.: The effect of simvastatin treatment on natural anti-oxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am. J. Cardiol. 77, 851–854 (1996)
- Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ: Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during shortterm simvastatin treatment in humans. Clin. Pharmacol. Ther. 57, 62–66 (1995)
- Paiva H, Thelen KM, Van Coster R et al.: High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin. Pharmacol. Ther. 78, 60–68 (2005).
- Documents changes in both intramuscular coenzyme Q10 levels and mitochondrial density in humans on high-dose statin therapy and raises the possibility that decreases in coenzyme Q10 are associated with mitochondria loss and not necessarily the cause of the mitochondrial dysfunction.old>
- Kelly P, Vasu S, Getato M, McNurlan M, Lawson WE: Coenzyme Q10 improves myopathic pain in statin treated patients. J. Am.Coll.Cardiol. 45, 3A (2005)
- Olson MF, Ashworth A, Hall A: An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 269, 1270–1272 (1995)
- Guijarro C, Blanco-Colio LM, Ortego M et al.: 3-hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ. Res. 83, 490–500 (1998)
- Wretman C, Lionikas A, Widegren U, Lannergren J, Westerblad H, Henriksson J: Effects of concentric and eccentric contractions on phosphorylation of MAPK(erk1/2) and MAPK(p38) in isolated rat skeletal muscle. J. Physiol. 535, 155–164 (2001)
- Widegren U, Wretman C, Lionikas A, Hedin G, Henriksson J: Influence of exercise intensity on ERK/MAPK signalling in human skeletal muscle. Pflugers Arch. 441, 317–322 (2000)
- Baker SK: Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 31, 572–580 (2005)
- Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR: Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 46, 1206–1210 (1997).
- Among the first studies to document that statins increase CK levels after eccentric exercise.old>
- Proske U, Morgan DL: Muscle damage from eccentric exercise: mechanism, mechanical signs, adaptation and clinical applications. J. Physiol. 537, 333–345 (2001)
- Evans WJ, Cannon JG: The metabolic effects of exercise-induced muscle damage. Exerc. Sport Sci. Rev. 19, 99–125 (1991)
- Thompson PD, Nugent AM, Herbert PN: Increases in creatine kinase after exercise in patients treated with HMG Co-A reductase inhibitors. JAMA 264, 2992 (1990)
- Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD: Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler. Thromb. Vasc. Biol. 25, 2560–2566 (2005)
- Franc S, Dejager S, Bruckert E, Chauvenet M, Giral P, Turpin G: A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc. Drugs Ther. 17, 459–465 (2003)
- Sinzinger H, O'Grady J: Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br. J. Clin. Pharmacol. 57, 525–528 (2004)
- Phillips PS, Phillips CT, Sullivan MJ, Naviaux RK, Haas RH: Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis 177, 183–188 (2004)
- Paolisso G, Barbagallo M, Petrella G et al.: Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 150, 121–127 (2000).
Future Lipidology
Volume 1, 2006 - Issue 2